LON:HIK Hikma Pharmaceuticals (HIK) Share Forecast, Price & News GBX 2,053 -35.00 (-1.68%) (As of 03:21 PM ET) Add Compare Share Share Today's Range 2,052▼ 2,09350-Day Range 2,040.87▼ 2,20552-Week Range 1,174.50▼ 2,222Volume311,955 shsAverage Volume427,955 shsMarket Capitalization£4.54 billionP/E Ratio3,801.85Dividend Yield2.44%Price TargetGBX 1,939.17 ProfileProfileAnalyst RatingsChartCompetitorsDividendInsider TradesHeadlinesSustainabilityProfileAnalyst RatingsChartCompetitorsDividendInsider TradesHeadlinesSustainability Hikma Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside6.0% DownsideGBX 1,939.17 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainability-2.61Upright™ Environmental ScoreNews Sentiment-0.21Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.40 out of 5 stars 1.3 Analyst's Opinion Consensus RatingHikma Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 1,939.17, Hikma Pharmaceuticals has a forecasted downside of 6.0% from its current price of GBX 2,062.Amount of Analyst CoverageHikma Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for HIK. Previous Next 0.8 Dividend Strength Dividend YieldHikma Pharmaceuticals pays a meaningful dividend of 2.35%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthHikma Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Hikma Pharmaceuticals is 9,259.26%. Payout ratios above 75% are not desirable because they may not be sustainable. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHikma Pharmaceuticals has received a 48.26% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Abiraterone", "Cancer medication (L01)", "Isosorbide dinitrate", and "HIV medication" products. See details.Environmental SustainabilityThe Environmental Impact score for Hikma Pharmaceuticals is -2.61. Previous Next 1.5 News and Social Media Coverage News SentimentHikma Pharmaceuticals has a news sentiment score of -0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Hikma Pharmaceuticals this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added Hikma Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hikma Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders30.73% of the stock of Hikma Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.98% of the stock of Hikma Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Hikma Pharmaceuticals is 3,818.52, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 107.61.Price to Earnings Ratio vs. SectorThe P/E ratio of Hikma Pharmaceuticals is 3,818.52, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 88.67.Price to Earnings Growth RatioHikma Pharmaceuticals has a PEG Ratio of 1.93. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHikma Pharmaceuticals has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Hikma Pharmaceuticals (LON:HIK) StockHikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms in North America, the Middle East, North Africa, and Europe. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company was founded in 1978 and is headquartered in London, the United Kingdom.Read More HIK Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HIK Stock News HeadlinesOctober 2, 2023 | markets.businessinsider.comCosmo and Hikma Sign License Agreement for Winlevi® in 17 Middle Eastern and North African CountriesSeptember 28, 2023 | msn.comGeneric drugs still out of reach despite effort to ensure accessOctober 2, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. September 27, 2023 | msn.comFTSE 100 sinks into the red despite gains for energy stocksSeptember 25, 2023 | msn.comPopular Children’s Antibiotic Liquid Amoxicillin Still In Shortage—Here Are Alternatives And What To KnowSeptember 7, 2023 | marketwatch.comArecor Therapeutics Partner Hikma Advances on Review of AT307 in USSeptember 6, 2023 | tmcnet.comHyloris Pharmaceuticals Reports 2023 Half-Year Results and provides Business OutlookAugust 31, 2023 | foxnews.comGeneric versions of Vyvanse released to address ADHD medicine shortage in USOctober 2, 2023 | PressReach (Ad)Nuclear Revival Creates Opportunities for UraniumUranium companies set to benefit from increased demand for clean energy.August 31, 2023 | msn.comM&S to make FTSE 100 comebackAugust 30, 2023 | ft.comMarks and Spencer to return to FTSE 100 after 4-year absenceAugust 30, 2023 | finance.yahoo.comMarks & Spencer Makes a Return to the FTSE 100 as Hiscox Loses Out in ReshuffleAugust 25, 2023 | finance.yahoo.comInotropic Agents Global Market Report 2023August 24, 2023 | uk.finance.yahoo.comGeneric Injectables Global Market Report 2023August 23, 2023 | msn.comResurgent M&S set for FTSE 100 return but builder Persimmon heads for the exitAugust 23, 2023 | msn.comDechra Pharmaceuticals set for promotion to FTSE 100 alongside M&SAugust 23, 2023 | yahoo.comFTSE 100 Live: London top flight seen higher ahead of PMI reading, US bank downgrades, Klarna sales boomAugust 22, 2023 | msn.comM&S set for FTSE 100 return but builder Persimmon heading for exitAugust 22, 2023 | benzinga.comPrefilled Syringes Market Size & Share to Surpass $10.59 Billion by 2030 | Vantage Market ResearchAugust 22, 2023 | msn.comM&S set for promotion back into Ftse-100 as it stages recoveryAugust 3, 2023 | msn.comHikma reports strong H1 performance, raises generics drugs guidanceAugust 3, 2023 | finance.yahoo.comTAKING ON THE OPIOID OVERDOSE EPIDEMIC IN NEW JERSEYAugust 3, 2023 | msn.comUK drugmaker Hikma raises annual outlook for generics armAugust 3, 2023 | marketwatch.comHikma Pharmaceutical 1H EPS 59.0cAugust 3, 2023 | nasdaq.comHikma Pharma H1 Profit Down, Revenues Up; Lifts FY23 Forecast For GenericsJuly 27, 2023 | finance.yahoo.comOctave Bioscience Closes $30M Extension to Series B FundingJuly 25, 2023 | finance.yahoo.comInhalation Anesthesia Global Market Report 2023: Technological Advancements Driving Strong Growth in the IndustrySee More Headlines Receive HIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address HIK Company Calendar Ex-Dividend for 9/15 Dividend8/10/2023Dividend Payable9/15/2023Today10/02/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON Industry Drug Manufacturers—Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolLON:HIK CUSIPN/A CIKN/A Webwww.hikma.com Phone+44-20-73992760FaxN/AEmployees8,700Year FoundedN/APrice Target and Rating Average Stock Price ForecastGBX 1,939.17 High Stock Price ForecastGBX 2,125 Low Stock Price ForecastGBX 1,740 Forecasted Upside/Downside-7.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 0.54 Trailing P/E Ratio3,866.67 Forward P/E Ratio12.85 P/E Growth1.93Net Income£146 million Net Margins5.35% Pretax MarginN/A Return on Equity6.74% Return on Assets8.06% Debt Debt-to-Equity Ratio59.58 Current Ratio1.79 Quick Ratio1.27 Sales & Book Value Annual Sales£2.73 billion Price / Sales1.69 Cash FlowGBX 250.39 per share Price / Cash Flow8.34 Book ValueGBX 990 per share Price / Book2.11Miscellaneous Outstanding Shares221,010,000Free FloatN/AMarket Cap£4.61 billion OptionableNot Optionable Beta0.43 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Mazen Samih Taleb Darwazah (Age 65)Exec. Vice Chairman & Pres of MENA Comp: $1.95MMr. Riad MishlawiChief Exec. OfficerMr. Khalid Waleed Hosny Al Nabilsi (Age 51)Chief Financial Officer Mr. Guy FeatherstoneAssociate Director of Investor RelationsMr. Bassam Wael Rushdi Kanaan CFA (Age 58)CPA, Exec. VP of Corp. Devel. and M&A Mr. Hussein Omar ArkhaghaChief HR Officer & Company Sec.Ms. Susan RingdalExec. VP of Strategic Planning & Global AffairsMr. Brian HoffmannPres of GenericsMr. Samuel ParkGlobal Head of Intellectual Property (IP) & Gen. Counsel for USMr. William Larkins Ph.D.Pres of Injectables Bus.More ExecutivesKey CompetitorsIndiviorLON:INDVHUTCHMEDLON:HCMConvaTec GroupLON:CTECDechra PharmaceuticalsLON:DPHMediclinic InternationalLON:MDCView All CompetitorsInsidersDouglas HurtBought 1,500 shares on 6/6/2023Total: £2.73 M ($1,820.00/share)Deneen VojtaBought 1,000 shares on 1/17/2023Total: £1.70 M ($1,703.00/share)View All Insider Transactions HIK Stock - Frequently Asked Questions Should I buy or sell Hikma Pharmaceuticals stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HIK shares. View HIK analyst ratings or view top-rated stocks. What is Hikma Pharmaceuticals' stock price forecast for 2023? 6 Wall Street analysts have issued 1-year target prices for Hikma Pharmaceuticals' stock. Their HIK share price forecasts range from GBX 1,740 to GBX 2,125. On average, they anticipate the company's stock price to reach GBX 1,939.17 in the next year. This suggests that the stock has a possible downside of 7.1%. View analysts price targets for HIK or view top-rated stocks among Wall Street analysts. How have HIK shares performed in 2023? Hikma Pharmaceuticals' stock was trading at GBX 1,552 on January 1st, 2023. Since then, HIK shares have increased by 34.5% and is now trading at GBX 2,088. View the best growth stocks for 2023 here. How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals? Hikma Pharmaceuticals announced a dividend on Thursday, August 3rd. Stockholders of record on Thursday, August 10th will be paid a dividend of GBX 0.25 per share on Friday, September 15th. This represents a dividend yield of 0.95%. The ex-dividend date of this dividend is Thursday, August 10th. The official announcement can be accessed at this link. Read our dividend analysis for HIK. Is Hikma Pharmaceuticals a good dividend stock? Hikma Pharmaceuticals (LON:HIK) pays an annual dividend of GBX 50 per share and currently has a dividend yield of 2.35%. The dividend payout ratio is 9,259.26%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for HIK. What other stocks do shareholders of Hikma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC). What is Hikma Pharmaceuticals' stock symbol? Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK." How do I buy shares of Hikma Pharmaceuticals? Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Hikma Pharmaceuticals' stock price today? One share of HIK stock can currently be purchased for approximately GBX 2,088. How much money does Hikma Pharmaceuticals make? Hikma Pharmaceuticals (LON:HIK) has a market capitalization of £4.61 billion and generates £2.73 billion in revenue each year. The company earns £146 million in net income (profit) each year or GBX 0.54 on an earnings per share basis. How many employees does Hikma Pharmaceuticals have? The company employs 8,700 workers across the globe. How can I contact Hikma Pharmaceuticals? Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The official website for the company is www.hikma.com. The company can be reached via phone at +44-20-73992760. This page (LON:HIK) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.